The New Science of Osteoarthritis Pain in Cats

At Zoetis, we have developed a new monoclonal antibody therapy that provides long-lasting osteoarthritis (OA) pain relief in cats by targeting nerve growth factor (NGF) in the pain pathway.

Sign-up and become one of the “1st to know” about this ground-breaking new therapy that aids in improving the quality of life in your feline OA patients.

Dr Duncan Lascelles

We will share short videos by key global opinion leaders including, Dr Duncan Lascelles, BSc, BVSc, PhD, FRCVS, CertVA, DSAS(ST), DECVS, DACVS, who will talk about nerve growth factor and novel anti-NGF therapy for OA pain cats.
References: 1. Foster Rosenblatt Zoetis Anti-NGF data on file. May 2019
SOLENSIA® is not a registered chemical product and contains frunevetmab which is not an approved active constituent. Applications for registration of the product and approval of the active constituent have been submitted to the Australian Pesticides and Veterinary Medicines Authority (APVMA).

zoetis.com.au | Privacy Policy | Terms of Use

Contact us at  marketing.au@zoetis.com or 1800 022 442
© Copyright 2026. Zoetis Inc. All rights reserved.
Zoetis Australia Pty Ltd ABN 94 156 476 4250.  Level 6, 5 Rider Boulevard, Rhodes, NSW 2138.

MM-16942